Cantor Fitzgerald and Jefferies Financial Group downgraded EyePoint Pharmaceuticals' stock rating from overweight/buy to neutral/hold on October 19, 2026.
2 reports, 1 independent
Updated Oct 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald and Jefferies Financial Group downgraded EyePoint Pharmaceuticals' stock rating from overweight/buy to neutral/hold on October 19, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
- The event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.
- Agilysys CEO Ramesh Srinivasan sold significant company shares, with the transaction disclosed via filings with the SEC, concurrent with a rating from Cantor Fitzgerald.
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Nothing else this week.
-
Jefferies Financial Group
American financial services company